Hyundai Bioscience현대바이오
048410 · KOSDAQ · ₩048410 · 현대바이오
₩5,820▼ ₩120 (2.02%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩3.5B | ₩15B | ₩9.5B | ₩7.9B | ₩9.2B |
| Cost of sales | ₩3.3B | ₩3.2B | ₩4.4B | ₩5.2B | ₩5.7B |
| Gross profit | ₩244M | ₩12B | ₩5B | ₩2.7B | ₩3.5B |
| Operating income | −₩18B | ₩791M | −₩9.8B | −₩26B | −₩9.8B |
| Net income | −₩22B | −₩6.9B | −₩14B | −₩16B | −₩20B |
| Net income to shareholders | −₩22B | −₩6.9B | −₩14B | −₩16B | −₩20B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩131B | ₩68B | ₩53B | ₩67B | ₩81B |
| Current assets | ₩44B | ₩6.8B | ₩15B | ₩24B | ₩35B |
| Cash and equivalents | ₩22B | ₩3.7B | ₩1.8B | ₩2.7B | ₩9.2B |
| Total liabilities | ₩20B | ₩28B | ₩7.5B | ₩9.1B | ₩19B |
| Current liabilities | ₩20B | ₩27B | ₩6.9B | ₩8.4B | ₩17B |
| Borrowings | ₩17B | ₩26B | ₩5.4B | ₩6B | ₩15B |
| Total equity | ₩111B | ₩39B | ₩45B | ₩58B | ₩62B |
| Shareholders' equity | ₩111B | ₩39B | ₩45B | ₩58B | ₩62B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩17B | ₩2.3B | −₩6B | −₩17B | −₩538M |
| Free cash flow | −₩17B | ₩2.3B | −₩6B | −₩17B | −₩538M |
Consolidated where available. Amounts in won.
Also known as: Hyundai Bioscience / 현대바이오 / 048410 / KRX:048410
Source: KRX statistical information